Acute Myelogenous Leukemia (AML)

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Bone Marrow Transplant

Dr. Han-Peter Kiem Decribes Bone Marrow Transplantation

Chemotherapy followed by a bone marrow transplant (also referred to as a stem cell transplant) may be used to treat relapsed acute myelogenous leukemia (AML) or AML in first remission. In this procedure, chemotherapy is used to destroy leukemia-producing bone marrow. Then disease-free stem cells from a compatible healthy donor (allogeneic transplant) are used to replenish the bone marrow with healthy cells. Sometimes the patient’s own bone marrow can be collected during remission and stored for later transplant (autologous transplant).

For many years, the source of normal stem cells for a transplant was the donor’s bone marrow. Today, however, the source is typically the donor’s blood.

Two other recent developments have extended the use of bone marrow transplants for AML patients. The first is known as mixed-chimerism transplant, which is less intensive than other types of transplants, making it suitable for older patients. The other development is ability to use compatible donors other than siblings (matched unrelated-donor transplant).

Because a bone marrow transplant is a complex procedure with significant side effects, it is important to have the procedure performed by an experienced medical team. At Seattle Cancer Care Alliance (SCCA), you will receive the highest standard of care from the world’s most experienced stem cell transplant physicians.

See our Bone Marrow Transplant section for more information about the different kinds of transplants and the process for getting a transplant at SCCA.